

Table 1.21  
U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2016<sup>a</sup>  
Using Different Tumor Inclusion Criteria<sup>b</sup>

Site	Sex	5-Year Limited Duration			24-year Limited Duration	
		1st Invasive Tumor Ever <sup>c</sup>	1st Per Site in Previous 24 Years <sup>d</sup>	1st Per Site in Previous 5 Years <sup>e</sup>	1st Invasive Tumor Ever <sup>c</sup>	1st Per Site in Previous 24 Years <sup>d</sup>
All Sites	Both Sexes	4,618,309	4,788,249	5,268,178	13,238,684	13,725,579
	Male	2,265,828	2,321,794	2,561,190	6,465,129	6,615,379
	Female	2,352,481	2,466,455	2,706,988	6,773,555	7,110,200
Oral Cavity & Pharynx	Both Sexes	116,614	137,601	142,958	285,683	322,983
	Male	83,745	97,382	100,597	197,295	220,172
	Female	32,869	40,219	42,361	88,388	102,811
Esophagus	Both Sexes	21,742	27,114	27,273	37,573	44,872
	Male	16,966	21,041	21,144	29,074	34,504
	Female	4,776	6,073	6,129	8,499	10,368
Stomach	Both Sexes	44,232	53,399	54,255	89,342	104,126
	Male	25,922	31,498	31,907	51,076	59,722
	Female	18,310	21,901	22,348	38,266	44,404
Colon & Rectum	Both Sexes	384,576	444,429	452,381	1,077,905	1,211,974
	Male	200,293	230,124	234,263	550,903	613,912
	Female	184,283	214,305	218,118	527,002	598,062
Liver & Intrahepatic Bile Duct	Both Sexes	48,352	56,128	56,342	70,556	80,067
	Male	34,831	39,846	40,003	50,338	56,224
	Female	13,521	16,282	16,339	20,218	23,843
Pancreas	Both Sexes	43,231	53,929	54,044	57,753	70,735
	Male	21,568	27,124	27,209	28,410	35,088
	Female	21,663	26,805	26,835	29,343	35,647
Larynx	Both Sexes	29,186	34,757	35,246	74,772	85,315
	Male	23,886	28,382	28,773	61,289	69,580
	Female	5,300	6,375	6,473	13,483	15,735
Lung & Bronchus	Both Sexes	224,901	296,258	307,825	387,582	494,958
	Male	102,077	135,269	139,706	170,233	217,057
	Female	122,824	160,989	168,119	217,349	277,901
Melanoma of the Skin	Both Sexes	291,465	340,956	359,793	897,922	1,003,650
	Male	161,053	191,955	204,571	469,112	530,596
	Female	130,412	149,001	155,222	428,810	473,054
Breast	Female	915,040	1,009,922	1,069,620	2,862,940	3,112,731
Cervix	Female	40,564	43,027	43,191	172,170	181,314
Corpus & Uterus, NOS	Female	200,697	225,923	226,147	575,275	636,687
Ovary <sup>f</sup>	Female	62,449	71,655	71,737	158,048	180,026

<sup>a</sup> U.S. 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 registries (not including the Alaska Natives Registry) and 1/1/2016 U.S. population estimates based on the average of 2015 and 2016 population estimates from the U.S. Bureau of the Census.

<sup>b</sup> Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

<sup>c</sup> (c) First invasive tumor ever

<sup>d</sup> (d) First invasive tumor for each cancer site diagnosed during the previous 24 years (1992-2015)

<sup>e</sup> (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2011-2015)

For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2011; Melanoma in 2012.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 24-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2016.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 24-year limited duration prevalence. The 2011 breast cancer is counted for the breast 5-year and 24-year limited duration prevalence.

In method (e) the 2011 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2012 melanoma is counted for 5-year limited duration prevalence for melanoma.

<sup>f</sup> Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Table 1.21 - continued  
 U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2016<sup>a</sup>  
 Using Different Tumor Inclusion Criteria<sup>b</sup>

Site	Sex	5-Year Limited Duration			24-year Limited Duration	
		1st Invasive Tumor Ever <sup>c</sup>	1st Per Site in Previous 24 Years <sup>d</sup>	1st Per Site in Previous 5 Years <sup>e</sup>	1st Invasive Tumor Ever <sup>c</sup>	1st Per Site in Previous 24 Years <sup>d</sup>
Prostate	Male	852,616	925,846	925,901	2,883,784	3,069,398
Testis	Male	43,378	44,309	44,823	180,132	183,792
Urinary Bladder	Both Sexes	201,203	254,235	260,387	528,898	631,413
	Male	154,809	195,876	200,971	400,452	477,786
	Female	46,394	58,359	59,416	128,446	153,627
Kidney & Renal Pelvis	Both Sexes	168,243	204,952	208,257	406,205	479,439
	Male	105,668	129,796	132,082	248,043	294,719
	Female	62,575	75,156	76,175	158,162	184,720
Brain & Nervous System	Both Sexes	44,838	48,165	48,639	121,093	126,388
	Male	24,984	26,796	27,023	64,923	67,482
	Female	19,854	21,369	21,616	56,170	58,906
Thyroid	Both Sexes	203,126	229,536	230,264	587,959	644,571
	Male	46,377	55,079	55,254	127,419	144,092
	Female	156,749	174,457	175,010	460,540	500,479
Hodgkin Lymphoma	Both Sexes	35,058	37,437	37,487	140,786	146,789
	Male	19,459	20,890	20,914	74,193	77,233
	Female	15,599	16,547	16,573	66,593	69,556
Non-Hodgkin Lymphoma	Both Sexes	209,115	248,946	254,357	566,981	644,761
	Male	113,015	135,137	138,113	300,944	342,069
	Female	96,100	113,809	116,244	266,037	302,692
Myeloma	Both Sexes	66,177	78,454	78,949	111,277	128,969
	Male	36,691	44,371	44,700	61,269	72,052
	Female	29,486	34,083	34,249	50,008	56,917
Leukemia	Both Sexes	130,295	153,253	153,837	336,170	376,508
	Male	76,451	90,192	90,566	193,982	217,145
	Female	53,844	63,061	63,271	142,188	159,363
Acute Lymphocytic Leukemia	Both Sexes	19,515	20,277	20,277	69,109	70,308
	Male	10,797	11,203	11,203	38,607	39,179
	Female	8,718	9,074	9,074	30,502	31,129
Childhood (Ages 0-19)	Both Sexes	67,096	67,129	67,682	264,287	264,940
	Male	35,300	35,299	35,549	139,152	139,459
	Female	31,796	31,830	32,133	125,135	125,481
Kaposi Sarcoma	Both Sexes	7,567	8,281	8,281	32,104	33,825
	Male	6,918	7,549	7,549	30,486	32,021
	Female	649	732	732	1,618	1,804
Mesothelioma	Both Sexes	3,199	4,257	4,257	4,536	5,767
	Male	2,203	2,983	2,983	2,834	3,687
	Female	996	1,274	1,274	1,702	2,080

<sup>a</sup> U.S. 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 9 registries and 1/1/2016 U.S. population estimates based on the average of 2015 and 2016 population estimates from the U.S. Bureau of the Census.

<sup>b</sup> Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

<sup>c</sup> (c) First invasive tumor ever  
<sup>d</sup> (d) First invasive tumor for each cancer site diagnosed during the previous 24 years (1992-2015)  
<sup>e</sup> (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2011-2015)  
 For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2011; Melanoma in 2012.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 24-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2016. In method (d) the 1981 melanoma is counted for the melanoma and all sites 24-year limited duration prevalence. The 2011 breast cancer is counted for the breast 5-year and 24-year limited duration prevalence. In method (e) the 2011 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2012 melanoma is counted for 5-year limited duration prevalence for melanoma.

Table 1.22  
U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2016<sup>a</sup>  
By Age at Prevalence

Site/Sex	Age at Prevalence								
	All Ages <sup>c</sup>	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
All Sites									
Males	7,046,820	19,013	45,658	92,312	168,663	324,888	900,095	1,901,064	3,595,127
Females	8,292,168	17,282	38,768	93,009	252,052	631,369	1,452,263	2,179,010	3,628,415
Oral Cavity & Pharynx									
Males	250,059	79	483	1,435	3,554	12,626	49,283	84,123	98,476
Females	120,250	80	486	1,591	3,870	8,272	20,688	31,925	53,339
Esophagus									
Males	35,559	0	0	29	183	903	4,460	11,824	18,160
Females	10,918	0	0	11	54	242	1,320	3,146	6,144
Stomach									
Males	64,837	0	24	160	789	2,727	9,103	17,395	34,640
Females	48,217	0	34	215	859	2,676	7,066	11,599	25,768
Colon & Rectum									
Males	661,406	19	310	1,521	6,867	26,306	95,856	171,638	358,889
Females	663,516	39	358	1,832	6,831	25,137	85,953	146,080	397,285
Liver & Intrahep									
Males	57,099	624	769	529	434	1,690	10,569	26,699	15,787
Females	25,982	541	654	392	562	1,249	3,991	9,069	9,525
Pancreas									
Males	36,418	8	58	120	525	1,740	5,902	11,974	16,091
Females	37,136	12	70	338	716	2,183	6,294	10,710	16,812
Larynx									
Males	78,929	6	8	102	246	1,565	8,956	22,799	45,246
Females	17,422	0	16	16	151	658	3,099	5,295	8,188
Lung & Bronchus									
Males	239,856	51	127	370	1,223	4,483	23,185	66,309	144,108
Females	298,387	42	71	411	1,456	5,877	32,254	76,338	181,938
Melanoma of the Skin									
Males	611,158	58	530	4,277	16,027	39,516	98,628	166,460	285,663
Females	584,451	109	657	8,033	31,954	66,800	124,763	146,768	205,367

<sup>a</sup> U.S. 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 areas not including the Alaska Natives Registry (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, Rural Georgia, San Jose-Monterey, and Los Angeles) and 1/1/2016 U.S. population estimates based on the average of 2015 and 2016 population estimates from the U.S. Bureau of the Census.

<sup>b</sup> Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years. Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

<sup>c</sup> Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.

Table 1.22 - continued  
 U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2016<sup>a</sup>  
 By Age at Prevalence

Site/Sex	Age at Prevalence								
	All Ages <sup>c</sup>	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
Breast									
Males	19,496	0	0	4	135	584	2,200	4,872	11,703
Females	3,477,866	16	25	3,276	39,571	207,774	602,250	975,728	1,649,227
Cervix									
Females	289,696	0	42	1,803	14,401	41,426	66,591	72,523	92,910
Corpus & Uterus, NOS									
Females	772,245	8	14	867	7,585	28,997	101,642	228,398	404,735
Ovary <sup>d</sup>									
Females	229,875	106	1,124	4,479	8,509	19,167	46,532	64,680	85,279
Prostate									
Males	3,110,403	24	52	54	206	14,018	217,572	865,480	2,012,997
Urinary Bladder									
Males	525,713	60	99	541	2,145	8,784	39,848	120,226	354,010
Females	173,737	49	64	251	979	3,027	13,312	36,306	119,749
Kidney & Renal Pelvis									
Males	326,154	1,538	2,140	2,609	9,271	21,911	54,924	92,324	141,438
Females	207,050	1,706	2,575	3,132	6,768	14,900	33,535	52,972	91,463
Hodgkin Lymphoma									
Males	108,576	179	2,567	9,822	15,519	21,451	26,921	19,909	12,208
Females	102,397	70	1,843	8,849	16,460	21,101	24,748	17,379	11,947
Non-Hodgkin Lymphoma									
Males	367,558	900	4,029	8,311	13,996	27,628	61,422	94,982	156,290
Females	327,146	521	1,769	4,696	10,164	21,105	48,512	82,379	157,999
Myeloma									
Males	72,999	0	8	83	680	3,390	11,695	22,552	34,593
Females	58,392	3	9	60	426	2,610	8,912	17,672	28,699
Leukemia									
Males	235,556	6,996	15,050	16,790	12,272	17,182	30,974	51,848	84,446
Females	179,217	6,251	11,682	13,694	10,821	13,891	22,189	34,672	66,018
Acute Lymphocytic Leuk									
Males	52,176	5,892	12,608	13,226	8,345	6,762	3,097	1,536	710
Females	43,589	5,242	9,971	10,290	7,475	5,610	2,594	1,532	874

<sup>a</sup> U.S. 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 areas not including the Alaska Natives Registry (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, Rural Georgia, San Jose-Monterey, and Los Angeles) and 1/1/2016 U.S. population estimates based on the average of 2015 and 2016 population estimates from the U.S. Bureau of the Census.

<sup>b</sup> Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years. Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

<sup>c</sup> Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.